Understanding the root cause for the falling stock price in the last 1.5 years.
Improved upside for future revenue growth with more indications.
Strong pipeline on Immunotherapy assets.
Slightly undervalued based on the fundamental analysis.
Editor's note: Seeking Alpha is proud to welcome Pharmyang Investment as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free